Jankel CA. FL. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9: 51–59.
Ostermann JK, Berghöfer A, Andersohn F, Fischer F. Frequency and clinical relevance of potential cytochrome P450 drug interactions in a psychiatric patient population–an analysis based on German insurance claims data. BMC Health Serv Res 2016; 16: 482.
Simpao AF AL, Desai BR, Bonafide CP, Galvez JA, Rehman MA, Jawad AF et al. Optimization of drug-drug interaction alert rules in a pediatric hospital's electronic health record system using a visual analytics dashboard. J Am Med Inform Assoc 2014; 22: 361–369.
Yeh ML CY, Wang PY, Li YC, Hsu CY. Physicians' responses to computerized drug-drug interaction alerts for outpatients. Comput Methods Programs Biomed 2013; 111: 17–25.
Taegtmeyer AB, Kullak-Ublick GA, Widmer N, Falk V, Jetter A. Clinical usefulness of electronic drug-drug interaction checking in the care of cardiovascular surgery inpatients. Cardiology 2012; 123: 219–222.
van Leeuwen RW JF, van den Bemt PM, de Man F, Piran F, Vincenten I, Jager A et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 2015; 26: 992–997.
van Leeuwen RW BD, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 2013; 108: 1071–1078.
Ellis JJ SA, Ten Eyck LL, Cappelleri JC, Brown CR, Suehs BT, Parsons B. Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia. Clinicoecon Outcomes Res 2014; 6: 389–399.
Teklay GSN, Legesse B, Bekele ML. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thromb J 2014; 12: 20.
Patel NNM, Koroglu A, Bliss S, Davis M, McNutt LA, Miller C. A cross-sectional study comparing the frequency of drug interactions after adding simeprevir- or sofosbuvir-containing therapy to medication profiles of hepatitis C monoinfected patients. Infect Dis Ther 2015.
Doan J Z-JH, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother 2013; 47: 324–332.
Secoli SR FA, Lebrão ML, de Lima FD, Santos JL. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging 2010; 27: 759–770.
Tulner LR, Frankfort SV, Gijsen GJ, Campen JPv, Koks CH, Beijnen JH. Drug-drug interactions in a geriatric outpatient cohort. Drugs Aging 2008; 25: 343–355.
Wong KYS, Holbrook A. A systematic review of medication safety outcomes related to drug interaction software. J Popul Ther Clin Pharmacol 2010; 17: e243–e255.
Zhou SF LJ, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89–295.
Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144.
Massachusetts All Payer Claims Database. Center for Health Information and Analysis (CHIA); (cited 2015); available from http://chiamass.gov/ma-apcd/.
Castro VM, McCoy TH, Cagan A, Rosenfield HR, Murphy SN, Churchill SE et al. Stratification of risk for hospital admissions for injury related to fall: cohort study. BMJ 2014; 349: g5863.
Perlis RH, Iosifescu DV, Castro VM, Murphy SN, Gainer VS, Minnier J et al. Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model. Psychol Med 2012; 42: 41–50.
Clements CC, Castro VM, Blumenthal SR, Rosenfield HR, Murphy SN, Fava M et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry 2014; 20: 727–734.
Murphy SN, Mendis M, Hackett K, Kuttan R, Pan W, Phillips LC et al. Architecture of the open-source clinical research chart from Informatics for Integrating Biology and the Bedside. AMIA Annu Symp Proc 2007; 11: 548–552.
Indiana University Department of Medicine. Flockhart Table: P450 Drug Interaction Table. 2016 (February 2016); available from http://medicine.iupui.edu/clinpharm/ddis/main-table/.
Healthcare Cost and Utilization Project (HCUP). Clinical Classifications Software (CCS) for ICD-9-CM. Agency for Healthcare Research and Quality, Rockville, MD; 2016 (March 2016); available from https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp#pubs.
Juurlink DN MM, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652–1658.
Pergolizzi JV Jr, Labhsetwar SA, Amy Puenpatom R, Ben-Joseph R, Ohsfeldt R, Summers KH. Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract 2012; 12: 45–56.
Malone DC HD, Haupert H, Hansten P, Duncan B, Van Bergen RC, Solomon SL et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 2005; 62: 1983–1991.
Grizzle AJ, Mahmood MH, Ko Y, Murphy JE, Armstrong EP, Skrepnek GH et al. Reasons provided by prescribers when overriding drug-drug interaction alerts. Am J Manag Care 2007; 13: 573–578.
Van Der Sijs H, Aarts J, Vulto A, Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 2006; 13: 138–147.